Last reviewed · How we verify
Alprazolam orally disintegrating tablets
Alprazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects.
Alprazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects. Used for Anxiety disorders, Panic disorder, Anxiety associated with depression.
At a glance
| Generic name | Alprazolam orally disintegrating tablets |
|---|---|
| Sponsor | UCB Pharma |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
Alprazolam binds to the benzodiazepine site on GABA-A receptors in the central nervous system, potentiating the inhibitory neurotransmitter GABA. This increases chloride ion influx into neurons, hyperpolarizing the cell membrane and reducing the likelihood of neuronal firing. The result is decreased anxiety, muscle relaxation, and sedation.
Approved indications
- Anxiety disorders
- Panic disorder
- Anxiety associated with depression
Common side effects
- Drowsiness
- Dizziness
- Fatigue
- Cognitive impairment
- Dependence/withdrawal risk
- Ataxia
Key clinical trials
- A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety (PHASE3)
- A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions (PHASE1)
- A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alprazolam orally disintegrating tablets CI brief — competitive landscape report
- Alprazolam orally disintegrating tablets updates RSS · CI watch RSS
- UCB Pharma portfolio CI